UA93201C2 - АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1 - Google Patents
АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1Info
- Publication number
- UA93201C2 UA93201C2 UAA200711364A UAA200711364A UA93201C2 UA 93201 C2 UA93201 C2 UA 93201C2 UA A200711364 A UAA200711364 A UA A200711364A UA A200711364 A UAA200711364 A UA A200711364A UA 93201 C2 UA93201 C2 UA 93201C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- human tgf
- tgf beta
- neutralizing human
- antibody neutralizing
- Prior art date
Links
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67408205P | 2005-04-22 | 2005-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93201C2 true UA93201C2 (ru) | 2011-01-25 |
Family
ID=37192643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200711364A UA93201C2 (ru) | 2005-04-22 | 2006-04-20 | АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7619069B2 (enExample) |
| EP (1) | EP1874818B1 (enExample) |
| JP (1) | JP5070200B2 (enExample) |
| KR (1) | KR100978684B1 (enExample) |
| CN (1) | CN101163719A (enExample) |
| AT (1) | ATE505489T1 (enExample) |
| AU (1) | AU2006240056B2 (enExample) |
| BR (1) | BRPI0608376A8 (enExample) |
| CA (1) | CA2607448C (enExample) |
| CY (1) | CY1111518T1 (enExample) |
| DE (1) | DE602006021292D1 (enExample) |
| DK (1) | DK1874818T3 (enExample) |
| EA (1) | EA016038B1 (enExample) |
| ES (1) | ES2361269T3 (enExample) |
| HR (1) | HRP20110334T1 (enExample) |
| IL (1) | IL186775A (enExample) |
| NO (1) | NO20076003L (enExample) |
| PL (1) | PL1874818T3 (enExample) |
| PT (1) | PT1874818E (enExample) |
| RS (1) | RS51845B (enExample) |
| SI (1) | SI1874818T1 (enExample) |
| UA (1) | UA93201C2 (enExample) |
| WO (1) | WO2006116002A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5564049B2 (ja) * | 2008-09-29 | 2014-07-30 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ１４７抗体、方法及び使用 |
| JP5735922B2 (ja) * | 2008-11-22 | 2015-06-17 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法 |
| US8685932B2 (en) * | 2008-12-16 | 2014-04-01 | Option Pharmaceuticals, Llc | Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases |
| CA2749115C (en) | 2009-01-09 | 2022-06-21 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US9289513B2 (en) | 2011-03-23 | 2016-03-22 | Option Pharmaceuticals, Llc | Targeted cytokine for treatment of musculoskeletal diseases |
| MY171135A (en) * | 2011-06-03 | 2019-09-27 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| SG10201604104PA (en) | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| US9518112B2 (en) | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
| EP2822871A4 (en) | 2012-03-08 | 2015-12-09 | Selig Sealing Products Inc | TANK SEALING ELEMENT WITH A PROTECTED SAFETY COMPONENT AND A REMOVAL BAG |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| PT3107573T (pt) * | 2014-02-19 | 2019-01-10 | Merck Patent Gmbh | Imunoterapia com il-12 visada ao cancro |
| GB2557389B (en) | 2015-01-14 | 2020-12-23 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| CU20180088A7 (es) | 2016-02-17 | 2019-05-03 | Novartis Ag | Anticuerpos anti tgfbeta 2 |
| AU2017222928A1 (en) * | 2016-02-26 | 2018-09-20 | Eli Lilly And Company | Anti-CD11d antibodies and uses thereof |
| JP2019509737A (ja) * | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| WO2017201036A1 (en) | 2016-05-17 | 2017-11-23 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| BR112018073861A2 (pt) * | 2016-05-20 | 2019-02-26 | President And Fellows Of Harvard College | métodos de terapia de genes para doenças e condições relacionadas com a idade |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| TW201811827A (zh) * | 2016-09-05 | 2018-04-01 | 日商中外製藥股份有限公司 | 抗ＴＧＦ－β１抗體及使用方法 |
| WO2018128939A1 (en) | 2017-01-05 | 2018-07-12 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| WO2019045086A1 (ja) * | 2017-08-29 | 2019-03-07 | 林化成株式会社 | 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途 |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| JP7544597B2 (ja) | 2017-11-06 | 2024-09-03 | ジェネンテック， インコーポレイテッド | がんの診断及び療法 |
| US11001635B2 (en) | 2018-06-29 | 2021-05-11 | Gensun Biopharma Inc. | Antitumor antagonists |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| MX2021009175A (es) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
| EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| MX2022008609A (es) | 2020-01-11 | 2022-11-10 | Scholar Rock Inc | Inhibidores de tgf¿ y uso de los mismos. |
| AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| MX2023015206A (es) * | 2021-06-18 | 2024-03-25 | Genzyme Corp | Formulaciones de anticuerpos anti-tgf-beta y su uso. |
| US20240301073A1 (en) | 2021-07-14 | 2024-09-12 | Scholar Rock, Inc. | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| EP1140041A2 (en) | 1999-01-05 | 2001-10-10 | University of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| WO2005010049A2 (en) * | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| DOP2005000108A (es) | 2004-06-04 | 2007-06-15 | Genentech Inc | Method for treating lupus |
| DK1931709T3 (en) * | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
-
2006
- 2006-04-20 PL PL06750860T patent/PL1874818T3/pl unknown
- 2006-04-20 DE DE602006021292T patent/DE602006021292D1/de active Active
- 2006-04-20 AT AT06750860T patent/ATE505489T1/de active
- 2006-04-20 PT PT06750860T patent/PT1874818E/pt unknown
- 2006-04-20 EA EA200702278A patent/EA016038B1/ru not_active IP Right Cessation
- 2006-04-20 CN CNA2006800135110A patent/CN101163719A/zh active Pending
- 2006-04-20 DK DK06750860.6T patent/DK1874818T3/da active
- 2006-04-20 KR KR1020077024149A patent/KR100978684B1/ko not_active Expired - Fee Related
- 2006-04-20 BR BRPI0608376A patent/BRPI0608376A8/pt not_active IP Right Cessation
- 2006-04-20 ES ES06750860T patent/ES2361269T3/es active Active
- 2006-04-20 EP EP06750860A patent/EP1874818B1/en active Active
- 2006-04-20 SI SI200631049T patent/SI1874818T1/sl unknown
- 2006-04-20 WO PCT/US2006/014943 patent/WO2006116002A2/en not_active Ceased
- 2006-04-20 JP JP2008507883A patent/JP5070200B2/ja not_active Expired - Fee Related
- 2006-04-20 HR HR20110334T patent/HRP20110334T1/hr unknown
- 2006-04-20 CA CA2607448A patent/CA2607448C/en not_active Expired - Fee Related
- 2006-04-20 AU AU2006240056A patent/AU2006240056B2/en not_active Ceased
- 2006-04-20 RS RS20110195A patent/RS51845B/sr unknown
- 2006-04-20 UA UAA200711364A patent/UA93201C2/ru unknown
-
2007
- 2007-10-18 IL IL186775A patent/IL186775A/en not_active IP Right Cessation
- 2007-10-19 US US11/874,952 patent/US7619069B2/en not_active Expired - Fee Related
- 2007-11-21 NO NO20076003A patent/NO20076003L/no not_active Application Discontinuation
-
2009
- 2009-10-15 US US12/579,447 patent/US8128927B2/en not_active Expired - Fee Related
-
2011
- 2011-05-13 CY CY20111100455T patent/CY1111518T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA93201C2 (ru) | АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1 | |
| TW200709817A (en) | Platform antibody compositions | |
| WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| UA100507C2 (ru) | Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd) | |
| UA100502C2 (ru) | Лечение prdc с применением антигена pcv2 | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| NZ594285A (en) | USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES | |
| MX2009006500A (es) | Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3. | |
| PL1830881T3 (pl) | Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie | |
| UA95304C2 (ru) | Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов | |
| MX2011000255A (es) | Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer. | |
| WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| TW200733974A (en) | Materials and methods for treating chronic fibrotic disease | |
| EA200701820A1 (ru) | Применение диосметиновых соединений при лечении и профилактике тромботических патологий | |
| EA200700273A1 (ru) | Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана | |
| UA101961C2 (xx) | Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| NZ596218A (en) | Bssl antagonists for treatment of inflammatory diseases |